Veeva Systems delivered strong financial performance with revenue growing 28% to $1.1B and operating income expanding 33% to $916M, while maintaining robust cash generation.
The company demonstrates healthy growth momentum across its life sciences software platform, with operating leverage evidenced by operating income growth outpacing revenue growth. The strong cash flow generation of $1.4B and reduced capital expenditures suggest efficient capital allocation and a maturing business model that requires less infrastructure investment.
Veeva's financial profile strengthened meaningfully with revenue reaching $1.1B and operating income growing to $916M, reflecting solid execution in the life sciences software market. The balance sheet expanded proportionally with total assets growing 22% to $9.0B and stockholders' equity increasing 24% to $7.2B, supported by strong cash generation. Notably, capital expenditures declined significantly to $3.1M while operating cash flow grew to $1.4B, indicating the business is generating substantial returns with minimal reinvestment needs.
Capex reduced 63.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Operating cash flow grew 29.8% — strong conversion of earnings to cash, healthy business fundamentals.
Revenue growing 28.1% — solid top-line momentum, watch margins for quality of growth.
Net income grew 27.3% — bottom-line growth signals improving overall business health.
Cash grew 27% — improving liquidity position supports investment and shareholder returns.
Current assets grew 26.8% — improving short-term liquidity or inventory/receivables build.
Receivables grew 23.9% — monitor days sales outstanding for collection efficiency.
Equity base grew 23.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 22.3% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →